T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.64% |
| 2 | Consumer Discretionary | 13.46% |
| 3 | Financials | 12.79% |
| 4 | Industrials | 12.13% |
| 5 | Technology | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Choice Hotels
CHH
$4.62B
| $396M | 0.09% |
8,400,433
-449,400
| -5% | -$20.2M |
|
277
Ball Corp
BALL
$16.6B
| $391M | 0.08% |
12,487,798
-346,898
| -3% | -$10.2M |
|
278
Micron Technology
MU
$981B
| $391M | 0.08% |
11,873,247
-787,401
| -6% | -$21.5M |
|
279
Diamondback Energy
FANG
$56.5B
| $387M | 0.08% |
4,363,419
-27,377
| -0.6% | -$2.08M |
|
280
Newmont
NEM
$124B
| $387M | 0.08% |
15,212,473
+444,600
| +3% | +$10.7M |
|
281
Fidelity National Information Services
FIS
$22.1B
| $385M | 0.08% |
7,035,942
+1,472,005
| +26% | +$79M |
|
|
BRCM
282
DELISTED
BROADCOM CORP CL-A
BRCM
| $385M | 0.08% |
10,370,816
-2,815,180
| -21% | -$92.3M |
|
|
HCC
283
DELISTED
HCC INSURANCES HOLDINGS INC
HCC
| $384M | 0.08% |
7,855,440
-23,070
| -0.3% | -$1.07M |
|
284
LPL Financial
LPLA
$29.2B
| $384M | 0.08% |
7,722,304
+1,165,908
| +18% | +$56.5M |
|
285
Norwegian Cruise Line
NCLH
$8.59B
| $383M | 0.08% |
12,086,200
+5,000
| +0% | +$162K |
|
286
Canadian Pacific Kansas City
CP
$80.8B
| $381M | 0.08% |
10,524,320
+1,942,515
| +23% | +$63.7M |
|
|
CVC
287
DELISTED
CABLEVISION SYS CP NY GRP CL-A
CVC
| $376M | 0.08% |
21,291,170
+312,500
| +1% | +$5.34M |
|
288
Petrobras
PBR
$116B
| $375M | 0.08% |
25,665,117
-79,275
| -0.3% | -$1.15M |
|
289
Cigna
CI
$72.4B
| $375M | 0.08% |
4,081,009
+318,810
| +8% | +$27.3M |
|
290
Lazard
LAZ
$4.24B
| $375M | 0.08% |
7,271,330
-72,000
| -1% | -$3.55M |
|
291
Trimble
TRMB
$13.5B
| $375M | 0.08% |
10,142,541
-3,379,779
| -25% | -$126M |
|
292
Capital One
COF
$134B
| $375M | 0.08% |
4,535,916
+920,349
| +25% | +$71.5M |
|
293
Ford
F
$55.7B
| $373M | 0.08% |
21,635,257
+123,020
| +0.6% | +$2M |
|
294
Jones Lang LaSalle
JLL
$16.7B
| $372M | 0.08% |
2,941,668
-18,884
| -0.6% | -$2.28M |
|
|
DGI
295
DELISTED
DigitalGlobe Inc.
DGI
| $372M | 0.08% |
13,368,603
-39,300
| -0.3% | -$1.18M |
|
296
Abbott
ABT
$190B
| $371M | 0.08% |
9,059,399
+3,033,770
| +50% | +$119M |
|
|
ATHN
297
DELISTED
Athenahealth, Inc.
ATHN
| $369M | 0.08% |
2,952,285
+799,642
| +37% | +$103M |
|
|
XEC
298
DELISTED
CIMAREX ENERGY CO
XEC
| $367M | 0.08% |
2,558,644
+653
| +0% | +$83.1K |
|
|
WFM
299
DELISTED
Whole Foods Market Inc
WFM
| $367M | 0.08% |
9,495,922
-14,663,334
| -61% | -$639M |
|
300
Stryker
SYK
$134B
| $367M | 0.08% |
4,347,186
-3,391,995
| -44% | -$277M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.